^
Association details:
| Biomarker: | LRP1B mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment
Published date:
03/22/2022
Excerpt:
A retrospective clinical study was conducted using 102 HCC patients who received ICI treatment to further verify whether gene mutations can predict the effectiveness of immunotherapy and prognosis of HCC....Results from the clinical study showed that HCC patients in the LRP1B mutation group had a poor response to ICI and worse prognosis than the wild-type group.
DOI:
https://doi.org/10.2147/JHC.S348785
